Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage…
By M. Markman, B. Bundy, D. Alberts, J. Fowler, D. L. Clark-Pearson, L. Carson, S. Wadler, Joshua Z. Sickel. Journal of Clinical Oncology, 2001
960 citations recorded by the source corpus.
Subfields: Oncology, Reproductive Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/8514faf8e2705eed863633dd0520dc30822b11a5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Reproductive Medicine
In Surgery
Citations in the corpus
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, neutral): “cycles compared with previous reported studies.(203) 204”
- Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, background): “The trial was unable to demonstrate an OS advantage, although a subset of the patients with a low CA 125 baseline did exhibit an improvement in survival.(68) Among the unanswered questions regarding this trial is whether the clinical benefit justifies the prolonged use of the agent with its inherent”
- A phase 3 trial of bevacizumab in ovarian cancer. (2011, neutral): “Any thromboembolic event None 708 (94) 665 (89) Grade 1 or 2 22 (3) 29 (4) Grade ≥3 23 (3) 51 (7) Venous thromboembolic event None 722 (96) 695 (93) Grade 1 or 2 18 (2) 18 (2) Grade ≥3 13 (2) 32 (4) Arterial thromboembolic event None 742 (99) 718 (96) Grade 1 or 2 1 (<1) 7 (1) Grade ≥3 10 (1) 20 (3)”